Bone Marrow Cytogenetics Test in Karachi at Dr. Essa Lab

Bone Marrow Cytogenetics at Dr. Essa Lab

Bone Marrow Cytogenetics is a highly specialized laboratory investigation designed to evaluate the numerical and structural integrity of chromosomes within bone marrow cells. This advanced genetic analysis is a cornerstone in modern hematopathology, playing an indispensable role in the diagnosis, classification, risk stratification, prognosis, and therapeutic monitoring of various hematological malignancies. By examining the karyotype of rapidly dividing hematological progenitor cells, cytogeneticists can identify specific chromosomal abnormalities such as translocations, deletions, duplications, inversions, and aneuploidies. These genetic signatures are often pathognomonic for specific diseases, guiding oncologists and hematologists in formulating precise, personalized treatment strategies.

At Dr. Essa Lab, a premier diagnostic institution in Karachi, Pakistan, Bone Marrow Cytogenetics is performed using state-of-the-art laboratory infrastructure and cutting-edge imaging software. The process involves culturing viable bone marrow aspirate cells, arresting them during metaphase when chromosomes are most condensed, and staining them to produce distinct banding patterns (G-banding). This allows for microscopic visualization and detailed analysis of the entire chromosome complement. The clinical value of this test is unparalleled, particularly in differentiating complex hematological conditions that present with similar clinical symptoms but require vastly different therapeutic interventions. Through precise cytogenetic profiling, Dr. Essa Lab assists clinicians in delivering evidence-based, targeted therapies that significantly improve patient outcomes.

Clinical Procedure: What to Expect

Patient Preparation

Because Bone Marrow Cytogenetics requires a bone marrow aspirate sample, patient preparation is critical to ensure safety, minimize discomfort, and preserve sample viability. Patients must observe the following preparation guidelines:

• Medical History Disclosure: Patients must inform their physician and the laboratory staff of all ongoing medications, particularly anticoagulants (such as warfarin, heparin, or enoxaparin) and antiplatelet drugs (such as aspirin or clopidogrel), as these can increase the risk of bleeding during the bone marrow aspiration procedure.
• Coagulation Profile: A recent Complete Blood Count (CBC) and Coagulation Profile (including PT, APTT, and INR) are typically required prior to the procedure to ensure the patient’s blood clotting mechanisms are within safe limits.
• Informed Consent: A detailed explanation of the bone marrow aspiration procedure will be provided, and the patient or an authorized guardian must sign an informed consent form.
• Fasting Requirements: While strict fasting is generally not required for local anesthesia, patients undergoing conscious sedation may be instructed to fast for 6 to 8 hours prior to the procedure.
• Allergy Notification: Patients must disclose any known allergies to local anesthetics (like lidocaine), antiseptics (such as iodine or chlorhexidine), or latex.

During the Procedure

The collection of the bone marrow specimen is an invasive clinical procedure performed by a qualified hematologist or oncologist under strict aseptic conditions. The step-by-step clinical process includes:

• Patient Positioning: The patient is typically asked to lie on their side (lateral decubitus position) or on their stomach (prone position) to expose the posterior superior iliac spine (hip bone), which is the most common and safest site for bone marrow aspiration.
• Skin Preparation and Local Anesthesia: The skin over the selected site is thoroughly cleansed with a surgical antiseptic. A local anesthetic is then injected into the skin, subcutaneous tissue, and the periosteum (the highly sensitive outer layer of the bone) to minimize pain.
• Aspiration Process: Once the area is completely numb, a specialized bone marrow aspiration needle is carefully inserted through the outer bone cortex into the marrow cavity. A syringe is attached to the needle, and approximately 2 to 3 milliliters of liquid bone marrow aspirate is drawn. The patient may experience a brief, sharp pulling or aching sensation during aspiration.
• Specimen Handling: The obtained aspirate is immediately transferred into specialized green-top tubes containing sodium heparin anticoagulant. This prevents clotting and preserves the viability of the living cells, which is absolutely critical for successful cell culturing in the cytogenetics laboratory.
• Post-Procedure Care: The needle is removed, and firm pressure is applied to the site for several minutes to stop any bleeding. A sterile pressure bandage is then applied. The patient is monitored for a short period before being allowed to return home.

When is a Bone Marrow Cytogenetics Performed?

Acute Myeloid Leukemia (AML) Diagnosis

In patients presenting with rapid-onset fatigue, frequent infections, easy bruising, and abnormal peripheral blood counts, Acute Myeloid Leukemia (AML) is a primary concern. Bone Marrow Cytogenetics is routinely performed at diagnosis to identify recurrent genetic abnormalities, such as the translocation t(8;21) or inversion inv(16). These cytogenetic markers categorize the leukemia into specific prognostic subgroups (favorable, intermediate, or adverse risk) according to the World Health Organization (WHO) classification, which directly dictates the intensity and type of chemotherapy or stem cell transplantation required.

Chronic Myeloid Leukemia (CML) Monitoring

Physicians request this test when Chronic Myeloid Leukemia (CML) is suspected due to persistent leukocytosis, splenomegaly, and fatigue. The test is essential for detecting the presence of the Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22, designated as t(9;22)(q34.1;q11.2). Beyond initial diagnosis, serial cytogenetic evaluations are performed to assess the patient’s cytogenetic response to Tyrosine Kinase Inhibitor (TKI) therapy and to monitor for clonal evolution, which indicates disease progression or drug resistance.

Myelodysplastic Syndromes (MDS) Prognostication

Myelodysplastic Syndromes (MDS) represent a group of clonal hematopoietic stem cell disorders characterized by cytopenias and dysplastic bone marrow features. Bone Marrow Cytogenetics is critical in MDS to confirm clonality and to calculate the International Prognostic Scoring System (IPSS-R) score. Detecting specific abnormalities, such as an isolated deletion of the long arm of chromosome 5 [del(5q)], carries favorable prognostic implications and predicts an excellent response to immunomodulatory therapies like lenalidomide, whereas complex karyotypes signal a high risk of transformation to acute leukemia.

Multiple Myeloma Evaluation

In patients presenting with bone pain, renal insufficiency, hypercalcemia, and anemia, Multiple Myeloma is suspected. Cytogenetic analysis, often supplemented by interphase Fluorescence In Situ Hybridization (FISH), is performed on bone marrow plasma cells. Identifying specific chromosomal abnormalities, such as the deletion of chromosome 17p [del(17p)] or translocations involving the immunoglobulin heavy chain locus on chromosome 14, is crucial for risk-stratifying the disease and selecting the most effective therapeutic agents, including proteasome inhibitors and immunomodulatory drugs.

Unexplained Cytopenias Investigation

When a patient presents with persistent, unexplained cytopenias (anemia, leukopenia, or thrombocytopenia) that cannot be attributed to nutritional deficiencies, autoimmune disorders, or drug side effects, a bone marrow evaluation is warranted. Performing cytogenetics on the bone marrow aspirate helps rule out occult hematological malignancies, early-stage myelodysplastic syndromes, or aplastic anemia by checking for clonal chromosomal abnormalities that may not be apparent through routine morphological examination alone.

What Does a Bone Marrow Cytogenetics Detect?

Bone Marrow Cytogenetics is capable of detecting a wide array of numerical and structural chromosomal abnormalities. The primary clinical findings include:

• Philadelphia Chromosome [t(9;22)(q34.1;q11.2)]: Diagnostic marker for Chronic Myeloid Leukemia (CML) and a high-risk prognostic marker in Acute Lymphoblastic Leukemia (ALL).
• t(15;17)(q24.1;q21.2): Results in the PML-RARA fusion gene, diagnostic of Acute Promyelocytic Leukemia (APML), requiring immediate targeted therapy with all-trans retinoic acid (ATRA).
• t(8;21)(q22;q22): Creates the RUNX1-RUNX1T1 fusion gene, associated with a favorable prognosis in Acute Myeloid Leukemia (AML).
• inv(16)(p13.1q22): Results in the CBFB-MYH11 fusion gene, another core-binding factor AML marker associated with a favorable treatment response.
• Monosomy 7 (-7): The loss of an entire chromosome 7, associated with poor prognosis in MDS and AML, often indicating resistance to standard chemotherapy.
• Deletion 5q [del(5q)]: Loss of a portion of the long arm of chromosome 5, defining a specific favorable-risk subtype of MDS.
• Trisomy 8 (+8): The presence of an extra chromosome 8, a common numerical abnormality in myeloid disorders, indicating clonal hematopoiesis.
• Deletion 20q [del(20q)]: A recurring structural abnormality in myeloproliferative neoplasms and MDS, generally associated with a favorable prognosis.
• Deletion 17p [del(17p)]: Loss of the TP53 tumor suppressor gene locus, associated with high-risk disease and drug resistance in CLL and Multiple Myeloma.
• t(11;14)(q13;q32): Associated with Mantle Cell Lymphoma and a subset of Multiple Myeloma patients.
• t(14;18)(q32;q21): Involves the BCL2 gene, characteristic of Follicular Lymphoma.
• Trisomy 12 (+12): A common numerical abnormality in Chronic Lymphocytic Leukemia (CLL), associated with intermediate risk.
• Deletion 11q [del(11q)]: Associated with extensive lymphadenopathy and disease progression in Chronic Lymphocytic Leukemia.
• Deletion 13q [del(13q)]: When occurring as an isolated abnormality in CLL, it is associated with a highly favorable prognosis and long survival times.
• t(1;19)(q23;p13.3): A structural translocation associated with pre-B cell Acute Lymphoblastic Leukemia.
• t(12;21)(p13.2;q22.1): Results in the ETV6-RUNX1 fusion gene, the most common genetic rearrangement in pediatric B-ALL, associated with an excellent prognosis.
• 11q23 Rearrangements (KMT2A/MLL): Associated with high-risk infant leukemias and therapy-related AML.
• Complex Karyotype: Defined as the presence of three or more unrelated cytogenetic abnormalities in a single clone, indicating genomic instability and poor prognosis.
• Monosomy 5 (-5): Associated with therapy-related myeloid neoplasms and adverse clinical outcomes.
• Isochromosome 17q [i(17q)]: A structural abnormality frequently associated with the blast phase of CML and high-risk MDS.
• Hyperdiploidy: The presence of more than 50 chromosomes, which is a highly favorable prognostic factor in pediatric B-ALL.
• Hypodiploidy: The presence of fewer than 44 chromosomes, representing an extremely high-risk feature in Acute Lymphoblastic Leukemia.
• Normal Male Karyotype (46,XY): Indicates no detectable numerical or structural chromosomal abnormalities in the analyzed cells of a male patient.
• Normal Female Karyotype (46,XX): Indicates no detectable numerical or structural chromosomal abnormalities in the analyzed cells of a female patient.

Turnaround Time and Report Access at Dr. Essa Lab

Due to the highly complex nature of cytogenetic testing, which requires culturing live cells for several days, harvesting, slide preparation, staining, and meticulous microscopic analysis of multiple metaphases, the turnaround time for Bone Marrow Cytogenetics at Dr. Essa Lab is typically between 10 to 14 working days. This timeline ensures that the cytogenetics team can perform a thorough and highly accurate analysis of at least 20 metaphases to confidently rule out low-level clonal abnormalities.

Dr. Essa Lab offers seamless report access for patients and referring physicians. Once the report is finalized and signed off by a Consultant Pathologist specializing in Cytogenetics, patients receive an automated SMS notification. Reports can be easily downloaded online via the official Dr. Essa Lab web portal or mobile application. Physical copies of the reports can also be collected from the main diagnostic center in Karachi or any of the conveniently located collection points across Pakistan.

Bone Marrow Cytogenetics Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Chromosome Number	46 chromosomes per cell (Diploid)	Aneuploidy (e.g., Monosomy -7, Trisomy +8, Hyperdiploidy, Hypodiploidy)
Sex Chromosomes	XX (Female) or XY (Male)	Loss of Y chromosome (-Y) in older males, structural sex chromosome abnormalities
Structural Rearrangements	No translocations, inversions, or insertions detected	Reciprocal translocations [e.g., t(9;22), t(15;17), t(8;21)] or inversions [e.g., inv(16)]
Chromosomal Deletions	Intact chromosomal arms with normal banding patterns	Microdeletions or large deletions [e.g., del(5q), del(7q), del(17p), del(13q)]
Clonal Evolution	Single normal diploid cell population	Multiple distinct abnormal clones indicating disease progression or resistance
Metaphases Analyzed	Minimum of 20 high-quality metaphases analyzed with normal karyotype	Fewer than 20 metaphases due to poor cell growth, or abnormal clones detected in analyzed cells
Banding Resolution	Clear, high-resolution G-banding patterns across all chromosomes	Poor resolution due to low mitotic index or suboptimal chromosome spreading

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Bone Marrow Cytogenetics?

• Experienced Healthcare Professionals: Dr. Essa Lab features a dedicated team of highly qualified consultant pathologists, clinical geneticists, and experienced laboratory technologists specializing in cytogenetic analysis.
• Patient-Focused Care: The laboratory prioritizes patient comfort, safety, and clear communication throughout the diagnostic journey.
• Quality Diagnostic Services: Dr. Essa Lab maintains rigorous internal quality control standards and participates in international external quality assurance programs to ensure the highest level of reporting accuracy.
• Professional Reporting: Cytogenetics reports are structured in strict accordance with the International System for Human Cytogenomic Nomenclature (ISCN), providing clear and actionable clinical insights for oncologists.
• Modern Diagnostic Approach: The laboratory utilizes advanced automated karyotyping systems and high-resolution imaging software to detect subtle structural chromosomal changes.
• Comfortable Environment: All collection centers and diagnostic facilities are designed to provide a clean, hygienic, and comfortable experience for patients.
• Convenient Location: With an extensive network of diagnostic centers and collection points across Karachi and other major cities, accessing services is highly convenient.
• Commitment to Accurate Diagnosis: Since its establishment in 1987, Dr. Essa Lab has remained committed to delivering precise, timely, and reliable diagnostic results to support effective clinical decision-making.